首页 | 官方网站   微博 | 高级检索  
     


Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results
Authors:Sumanta K Pal MD  Dean Bajorin MD  Nazli Dizman MD  Jean Hoffman-Censits MD  David I Quinn MD  Daniel P Petrylak MD  Matthew D Galsky MD  Ulka Vaishampayan MD  Ugo De Giorgi MD  Sumati Gupta MD  Howard A Burris MD  Harris S Soifer PhD  Gary Li PhD  Hao Wang PhD  Carl L Dambkowski MD  Susan Moran MD  Siamak Daneshmand MD  Jonathan E Rosenberg MD
Affiliation:1. Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California;2. Genitourinary Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Department of Medicine, Weill Cornell Medical College, New York, New York;3. Departments of Medical Oncology and Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania;4. University of Southern California Norris Comprehensive Cancer Center Keck School of Medicine at USC, Los Angeles, California;5. Department of Medicine, Division of Oncology, Yale School of Medicine, New Haven, Connecticut;6. Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, The Mount Sinai Hospital, New York, New York;7. Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan;8. Department of Medical Oncology, Scientific Institute of Romagna for the Study and Treatment of Cancer, IRCCS, Meldola, Italy;9. Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah;10. Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee;11. Department of Translational Medicine, QED Therapeutics Inc, San Francisco, California;12. Department of Biostatistics and Data Management, QED Therapeutics Inc, San Francisco, California;13. Department of Strategy and Operations, QED Therapeutics Inc, San Francisco, California;14. Department of Clinical Development, QED Therapeutics Inc, San Francisco, California;15. Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California;16. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Abstract:
Keywords:FGFR3  genomic profile  lower tract urothelial carcinoma  upper tract urothelial carcinoma
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号